{
    "clinical_study": {
        "@rank": "53508", 
        "arm_group": [
            {
                "arm_group_label": "MK-3222 200 mg", 
                "arm_group_type": "Experimental", 
                "description": "MK-3222 administered subcutaneously (SC) at a dose of 200 mg at Week 0 and Week 4, and then every 12 weeks until study end or participant discontinuation."
            }, 
            {
                "arm_group_label": "MK-3222 100 mg", 
                "arm_group_type": "Experimental", 
                "description": "MK-3222 administered SC at a dose of 100 mg at Week 0 and Week 4, and then every 12 weeks until study end or participant discontinuation."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Matching placebo administered SC at Week 0 and Week 4."
            }
        ], 
        "brief_summary": {
            "textblock": "This study is being conducted to evaluate the efficacy and safety/tolerability of\n      subcutaneous MK-3222, followed by an optional long-term safety\n\n      extension study, in participants with moderate-to-severe chronic plaque psoriasis."
        }, 
        "brief_title": "A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010)", 
        "completion_date": {
            "#text": "August 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Plaque Psoriasis", 
        "condition_browse": {
            "mesh_term": "Psoriasis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Clinical diagnosis of moderate-to-severe plaque psoriasis for at least 6 months prior\n             to study enrollment\n\n          -  A candidate for phototherapy or systemic therapy\n\n          -  For the extension study: must have completed Part 3 of the base study\n\n          -  For the extension study: must have achieved at least a PASI-50 response by the end of\n             Part 3 of the base study\n\n          -  For the extension study: must have received active MK-3222 treatment within 12 weeks\n             prior to the end of Part 3 of the base study\n\n          -  Premenopausal female participants must agree to abstain from heterosexual activity or\n             use a medically accepted method of contraception or use appropriate effective\n             contraception as per local regulations or guidelines\n\n          -  If enrolled at a Japanese site, participants with psoriatic arthritis using\n             non-steroidal anti-inflammatory drugs (NSAIDs) must be on a stable dose for at least\n             4 weeks prior to the first dose of study drug and must not be expected to require an\n             increase in dose over the course of the study\n\n        Exclusion Criteria:\n\n          -  Has erythrodermic psoriasis, predominantly pustular psoriasis, medication-induced or\n             medication-exacerbated psoriasis, or new onset guttate psoriasis\n\n          -  Current or history of severe psoriatic arthritis and is well-controlled on current\n             treatment\n\n          -  Women of child-bearing potential that are pregnant, intend to become pregnant within\n             6 months of completing the trial, or that are breast feeding\n\n          -  Expected to require topical treatment, phototherapy, or systemic treatment during the\n             trial\n\n          -  Presence of any infection\n\n          -  History of recurrent infection requiring treatment with systemic antibiotics within 2\n             weeks of screening\n\n          -  Previous use of MK-3222 or other IL-23/Th-17 pathway inhibitors including P40, p19,\n             and IL-17 antagonists\n\n          -  Evidence of active or untreated latent tuberculosis (TB)\n\n          -  Positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen\n             (HBs Ag) or hepatitis C virus (HCV)\n\n          -  At Japanese sites, positive test for HBs antibody and hepatitis B virus (HBV)\n             deoxyribonucleic acid (DNA)\n\n          -  At Japanese sites, positive test for the Hepatitis B core (HBc) antibody and HBV DNA\n\n          -  For the extension study: women of child-bearing potential that are pregnant, intend\n             to become pregnant within 6 months of completing the trial, or that are breast\n             feeding\n\n          -  For the extension study: active or uncontrolled significant organ dysfunction or\n             clinically significant laboratory abnormalities\n\n          -  For the extension study: expected to require topical treatment, phototherapy, or\n             systemic treatment during the extension study\n\n          -  At Japanese sites, abnormal for Beta D Glucan and/or KL-6 test result(s) at the\n             screening visit."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "885", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 2, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01722331", 
            "org_study_id": "3222-010", 
            "secondary_id": [
                "2012-002255-42", 
                "P07770"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "MK-3222 200 mg", 
                "intervention_name": "MK-3222 200 mg", 
                "intervention_type": "Drug", 
                "other_name": "SCH 900222"
            }, 
            {
                "arm_group_label": "MK-3222 100 mg", 
                "intervention_name": "MK-3222 100 mg", 
                "intervention_type": "Drug", 
                "other_name": "SCH 900222"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Matching Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 3, 2014", 
        "number_of_arms": "3", 
        "official_title": "A 64-Week, Phase 3, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222), Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis (Protocol No. MK-3222-010)", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Proportion of Participants With Psoriasis Area Sensitivity Index 75 (PASI-75) Response at Week 12", 
                "safety_issue": "No", 
                "time_frame": "Week 12"
            }, 
            {
                "measure": "Proportion of Participants With a Physician's Global Assessment (PGA) Score of Clear or Minimal With at Least a 2 Grade Reduction From Baseline at Week 12", 
                "safety_issue": "No", 
                "time_frame": "Week 12"
            }, 
            {
                "measure": "Number of Participants Experiencing Adverse Events (AEs)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 276"
            }, 
            {
                "measure": "Number of Participants Discontinuing Due to Drug-Related AEs", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 276"
            }, 
            {
                "measure": "Number of Participants Experiencing an AE Up to Week 12", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 12"
            }, 
            {
                "measure": "Number of Participants Discontinuing Study Treatment Due to an AE Up to Week 12", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 12"
            }
        ], 
        "removed_countries": {
            "country": [
                "United States", 
                "Canada", 
                "Japan", 
                "United Kingdom", 
                "Australia"
            ]
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01722331"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Proportion of Participants With PASI-90 Response At Week 12", 
                "safety_issue": "No", 
                "time_frame": "Week 12"
            }, 
            {
                "measure": "Proportion of Participants With PASI-100 Response at Week 12", 
                "safety_issue": "No", 
                "time_frame": "Week 12"
            }, 
            {
                "measure": "Change From Baseline in the Participant Dermatology Life Quality Index (DLQI) at Week 12", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 12"
            }, 
            {
                "measure": "Proportion of Participants With DLQI Score of 0 or 1 at Week 12", 
                "safety_issue": "No", 
                "time_frame": "Week 12"
            }
        ], 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}